Log in

NASDAQ:ATRIAtrion Competitors & Alternatives

$637.29
+6.21 (+0.98 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$624.50
Now: $637.29
$637.29
50-Day Range
$619.53
MA: $649.66
$666.00
52-Week Range
$579.00
Now: $637.29
$846.15
Volume4,900 shs
Average Volume5,809 shs
Market Capitalization$1.17 billion
P/E Ratio32.77
Dividend Yield0.98%
Beta0.17

Competitors

Atrion (NASDAQ:ATRI) Vs. ALGN, WST, COO, QDEL, XRAY, and HAE

Should you be buying ATRI stock or one of its competitors? Companies in the sub-industry of "health care supplies" are considered alternatives and competitors to Atrion, including Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), Quidel (QDEL), DENTSPLY SIRONA (XRAY), and Haemonetics (HAE).

Atrion (NASDAQ:ATRI) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Atrion and Align Technology, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
Align Technology04902.69

Align Technology has a consensus target price of $254.8182, indicating a potential downside of 6.76%. Given Align Technology's higher possible upside, analysts plainly believe Align Technology is more favorable than Atrion.

Volatility & Risk

Atrion has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500.

Profitability

This table compares Atrion and Align Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion23.06%15.57%14.09%
Align Technology78.42%107.18%66.05%

Insider and Institutional Ownership

65.8% of Atrion shares are held by institutional investors. Comparatively, 86.0% of Align Technology shares are held by institutional investors. 22.4% of Atrion shares are held by company insiders. Comparatively, 1.2% of Align Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Atrion and Align Technology's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.56$36.76 millionN/AN/A
Align Technology$2.41 billion8.94$442.78 million$4.9655.10

Align Technology has higher revenue and earnings than Atrion.

Summary

Align Technology beats Atrion on 10 of the 12 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation.

Valuation & Earnings

This table compares Atrion and West Pharmaceutical Services' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.56$36.76 millionN/AN/A
West Pharmaceutical Services$1.84 billion9.29$241.70 million$3.2471.68

West Pharmaceutical Services has higher revenue and earnings than Atrion.

Dividends

Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. West Pharmaceutical Services pays an annual dividend of $0.64 per share and has a dividend yield of 0.3%. West Pharmaceutical Services pays out 19.8% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years and West Pharmaceutical Services has increased its dividend for 27 consecutive years.

Profitability

This table compares Atrion and West Pharmaceutical Services' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion23.06%15.57%14.09%
West Pharmaceutical Services13.80%17.69%11.94%

Insider and Institutional Ownership

65.8% of Atrion shares are owned by institutional investors. Comparatively, 90.6% of West Pharmaceutical Services shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Atrion has a beta of 0.17, suggesting that its stock price is 83% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its stock price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Atrion and West Pharmaceutical Services, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
West Pharmaceutical Services01002.00

West Pharmaceutical Services has a consensus target price of $200.00, suggesting a potential downside of 13.88%. Given West Pharmaceutical Services' higher probable upside, analysts plainly believe West Pharmaceutical Services is more favorable than Atrion.

Summary

West Pharmaceutical Services beats Atrion on 9 of the 14 factors compared between the two stocks.

Atrion (NASDAQ:ATRI) and Cooper Companies (NYSE:COO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

Earnings & Valuation

This table compares Atrion and Cooper Companies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atrion$155.07 million7.56$36.76 millionN/AN/A
Cooper Companies$2.65 billion5.82$466.70 million$12.3523.43

Cooper Companies has higher revenue and earnings than Atrion.

Dividends

Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. Cooper Companies pays out 0.5% of its earnings in the form of a dividend. Atrion has increased its dividend for 17 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Atrion and Cooper Companies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Atrion23.06%15.57%14.09%
Cooper Companies13.50%14.67%8.40%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Atrion and Cooper Companies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Atrion0000N/A
Cooper Companies03802.73

Cooper Companies has a consensus price target of $330.7273, suggesting a potential upside of 14.28%. Given Cooper Companies' higher possible upside, analysts plainly believe Cooper Companies is more favorable than Atrion.

Institutional & Insider Ownership

65.8% of Atrion shares are owned by institutional investors. Comparatively, 88.1% of Cooper Companies shares are owned by institutional investors. 22.4% of Atrion shares are owned by insiders. Comparatively, 1.4% of Cooper Companies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Atrion has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500. Comparatively, Cooper Companies has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500.

Summary

Atrion beats Cooper Companies on 8 of the 15 factors compared between the two stocks.

Quidel (NASDAQ:QDEL) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, analyst recommendations, risk, institutional ownership, profitability and earnings.

Insider and Institutional Ownership

87.0% of Quidel shares are held by institutional investors. Comparatively, 65.8% of Atrion shares are held by institutional investors. 14.1% of Quidel shares are held by company insiders. Comparatively, 22.4% of Atrion shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Quidel and Atrion's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quidel$534.89 million19.37$72.92 million$2.7390.34
Atrion$155.07 million7.56$36.76 millionN/AN/A

Quidel has higher revenue and earnings than Atrion.

Profitability

This table compares Quidel and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Quidel15.73%23.69%14.58%
Atrion23.06%15.57%14.09%

Analyst Recommendations

This is a breakdown of recent ratings for Quidel and Atrion, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Quidel12302.33
Atrion0000N/A

Quidel currently has a consensus target price of $161.8333, indicating a potential downside of 34.38%. Given Quidel's higher possible upside, equities research analysts clearly believe Quidel is more favorable than Atrion.

Volatility & Risk

Quidel has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

Quidel beats Atrion on 10 of the 12 factors compared between the two stocks.

DENTSPLY SIRONA (NASDAQ:XRAY) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, valuation, dividends, risk and earnings.

Analyst Recommendations

This is a summary of recent ratings and price targets for DENTSPLY SIRONA and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DENTSPLY SIRONA07602.46
Atrion0000N/A

DENTSPLY SIRONA currently has a consensus price target of $49.1538, indicating a potential upside of 17.09%. Given DENTSPLY SIRONA's higher probable upside, research analysts clearly believe DENTSPLY SIRONA is more favorable than Atrion.

Valuation and Earnings

This table compares DENTSPLY SIRONA and Atrion's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DENTSPLY SIRONA$4.03 billion2.28$262.90 million$2.4517.13
Atrion$155.07 million7.56$36.76 millionN/AN/A

DENTSPLY SIRONA has higher revenue and earnings than Atrion.

Institutional and Insider Ownership

95.4% of DENTSPLY SIRONA shares are held by institutional investors. Comparatively, 65.8% of Atrion shares are held by institutional investors. 0.5% of DENTSPLY SIRONA shares are held by insiders. Comparatively, 22.4% of Atrion shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Dividends

DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 1.0%. Atrion pays an annual dividend of $6.20 per share and has a dividend yield of 1.0%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. DENTSPLY SIRONA has raised its dividend for 8 consecutive years and Atrion has raised its dividend for 17 consecutive years. Atrion is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares DENTSPLY SIRONA and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DENTSPLY SIRONA2.12%10.70%6.38%
Atrion23.06%15.57%14.09%

Risk and Volatility

DENTSPLY SIRONA has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, indicating that its share price is 83% less volatile than the S&P 500.

Summary

Atrion beats DENTSPLY SIRONA on 8 of the 15 factors compared between the two stocks.

Haemonetics (NYSE:HAE) and Atrion (NASDAQ:ATRI) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Institutional and Insider Ownership

99.2% of Haemonetics shares are owned by institutional investors. Comparatively, 65.8% of Atrion shares are owned by institutional investors. 1.6% of Haemonetics shares are owned by insiders. Comparatively, 22.4% of Atrion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Haemonetics has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. Comparatively, Atrion has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500.

Earnings and Valuation

This table compares Haemonetics and Atrion's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Haemonetics$988.48 million4.43$76.53 million$3.3126.31
Atrion$155.07 million7.56$36.76 millionN/AN/A

Haemonetics has higher revenue and earnings than Atrion.

Profitability

This table compares Haemonetics and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Haemonetics7.74%29.33%13.83%
Atrion23.06%15.57%14.09%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Haemonetics and Atrion, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Haemonetics01602.86
Atrion0000N/A

Haemonetics currently has a consensus price target of $130.1667, indicating a potential upside of 49.45%. Given Haemonetics' higher probable upside, analysts clearly believe Haemonetics is more favorable than Atrion.

Summary

Haemonetics beats Atrion on 8 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Align Technology logo
ALGN
Align Technology
1.9$273.29+0.3%$21.59 billion$2.41 billion11.46
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.6$232.23+1.6%$17.10 billion$1.84 billion67.12
Cooper Companies logo
COO
Cooper Companies
2.7$289.39+0.1%$15.45 billion$2.65 billion42.12Insider Buying
Quidel logo
QDEL
Quidel
1.1$246.64+0.7%$10.27 billion$534.89 million120.31Analyst Report
Increase in Short Interest
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.2$41.98+1.7%$9.20 billion$4.03 billion113.46Analyst Downgrade
Decrease in Short Interest
Haemonetics logo
HAE
Haemonetics
1.6$87.10+2.8%$4.38 billion$988.48 million59.25Analyst Report
Neogen logo
NEOG
Neogen
1.0$77.39+0.5%$4.08 billion$414.19 million69.10
ICU Medical logo
ICUI
ICU Medical
1.5$180.55+1.9%$3.76 billion$1.27 billion44.69Analyst Downgrade
STAAR Surgical logo
STAA
STAAR Surgical
1.5$58.44+0.3%$2.67 billion$150.18 million216.45Analyst Report
Unusual Options Activity
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.6$43.24+1.2%$2.39 billion$994.85 million-540.43
Cerus logo
CERS
Cerus
1.2$7.00+1.0%$1.15 billion$74.65 million-14.58Analyst Downgrade
Insider Selling
Meridian Bioscience logo
VIVO
Meridian Bioscience
0.9$23.93+4.3%$1.05 billion$201.01 million46.92Increase in Short Interest
OraSure Technologies logo
OSUR
OraSure Technologies
1.1$13.42+3.2%$829.82 million$154.60 million67.10Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.9$35.35+1.6%$493.66 million$114.51 million19.32Analyst Upgrade
Antares Pharma logo
ATRS
Antares Pharma
1.9$2.60+0.8%$427.15 million$123.86 million130.07Analyst Upgrade
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$82.78+3.8%$312.99 million$46.90 million21.01
RTI Surgical logo
RTIX
RTI Surgical
1.5$2.92+5.8%$205.15 million$308.38 million-0.97
Endologix logo
ELGX
Endologix
1.6$0.27+18.5%$6.11 million$143.37 million-0.08Analyst Downgrade
High Trading Volume
This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.